Locations
New Lambton Heights NSW 2305, Australia · New South Wales, Australia
industry
Biotechnology · DeepTech · Health
Stage
Series B
founded in
2019
Imm Vir X is a clinical stage oncology company focused on developing receptor targeted oncolytic RNA immunotherapies aimed at providing powerful and durable responses for prevalent cancers with high unmet needs. The company leverages proprietary bio-selected RNA viruses that selectively infect and kill cancer cells while inducing systemic anti-tumor immune responses. Their innovative approach enhances the effectiveness of existing therapies, such as immune checkpoint inhibitors and CAR-T cells, targeting difficult-to-treat cancers like colorectal, gastric, hepatocellular, and ovarian cancer. Founded by a team from Viralytics, Imm Vir X is progressing clinical trials based on extensive pre-clinical and manufacturing data, positioning itself as a leader in the oncolytic immunotherapy space.
Something looks off?